Revvity Reports 2% Revenue Growth to $698.9 Million in Q3 2025

Revvity, Inc. reported its financial results for the third quarter of fiscal year 2025, revealing total revenue of $698.9 million, a 2% increase from $684.0 million in the same period last year. The growth was driven by a 3% rise in the Diagnostics segment, which generated $356.1 million, and a 1% increase in the Life Sciences segment, which brought in $342.8 million. However, the company experienced a decline in net income, which fell to $46.7 million from $94.4 million year-over-year, primarily due to increased costs and unfavorable foreign exchange rates.

For the nine months ending September 28, 2025, Revvity's total revenue reached $2.08 billion, up from $2.03 billion in the prior year, marking a 3% increase. The Life Sciences segment contributed $1.05 billion, while the Diagnostics segment accounted for $1.03 billion. Despite the revenue growth, the company reported a decrease in operating income from continuing operations, which was $244.9 million for the nine-month period, compared to $227.9 million in the previous year. This decline was attributed to rising costs, including tariffs and changes in product mix.

In terms of strategic developments, Revvity has integrated its Applied Genomics business into a newly formed Life Sciences Solutions segment, enhancing its focus on life sciences reagents and services. The company also continued its stock repurchase program, having repurchased 2.3 million shares at a cost of approximately $204.9 million during the quarter. As of September 28, 2025, Revvity had $931.4 million in cash and cash equivalents, with $1.5 billion available under its senior unsecured revolving credit facility.

Operationally, Revvity's customer base and engagement metrics remained stable, with a focus on expanding its market presence. The company reported a decrease in gross margins, which fell to 53.6% from 56.3% year-over-year, primarily due to increased tariffs and unfavorable foreign exchange impacts. The company is actively implementing strategies to mitigate these cost pressures, including manufacturing optimization and selective pricing actions.

Looking ahead, Revvity anticipates continued revenue growth driven by its strategic focus on life sciences and diagnostics. However, the company remains cautious about potential market fluctuations and regulatory changes that could impact its operations. The management expects to maintain a strong cash position to support ongoing investments and shareholder returns while navigating the challenges posed by the current economic environment.